# Backend Restart Required

## Current Status

✅ **All backend code changes have been successfully applied:**
- SQL database integration complete
- Matching algorithm fixes applied (5 critical fixes)
- Python bytecode cache cleared
- Debug script confirms bc_trial_005 now matches (6 trials total for Patient A)

## Issue

The backend server running in Terminal 9 needs to be manually restarted to pick up the changes.

**Current Result:** API returns 5 trials (missing bc_trial_005)
**Expected Result:** API should return 6 trials (including bc_trial_005)

## Solution: Manual Restart Required

### Step 1: Stop the Backend
1. Click on **Terminal 9** in VS Code
2. Press **Ctrl+C** to stop the running server
3. Wait for the process to fully stop

### Step 2: Restart the Backend
In Terminal 9, run:
```bash
cd trialscout-backend
python -m app.main
```

Wait for the message: `INFO:     Uvicorn running on http://0.0.0.0:8000`

### Step 3: Test the Fix
Run this command in a new terminal:
```bash
curl -X POST http://localhost:8000/api/v1/match -H "Content-Type: application/json" -d @test_patient_a.json
```

**Expected output:**
```json
{
  "stats": {
    "total_trials": 20,
    "possibly_eligible": 6,  ← Should be 6 (was 5)
    "hard_excluded": 14
  }
}
```

**Matched trials should include:**
1. bc_trial_001 - DESTINY-Breast06 (HER2-Low)
2. bc_trial_002 - Sacituzumab Govitecan (HR+/HER2-)
3. bc_trial_004 - Elacestrant (ESR1-Mutant)
4. **bc_trial_005 - Datopotamab Deruxtecan (HR+/HER2- or TNBC)** ← This was missing
5. bc_trial_007 - Capivasertib (PIK3CA/AKT1/PTEN)
6. bc_trial_009 - Rintodestrant (ER+/HER2-)

## Verification

To verify the fix is working, you can also run the debug script:
```bash
cd trialscout-backend
python debug_matching.py
```

This should show:
```
SUMMARY: 6 matched, 4 excluded
```

## What Was Fixed

### Fix #5: TNBC Exclusion Logic
**File:** `trialscout-backend/app/matching/rules.py` (lines 96-101)

**Problem:** Trial bc_trial_005 has title "Datopotamab Deruxtecan in HR+/HER2- or Triple-Negative..." 
The TNBC exclusion rule was excluding ER+ patients even though the trial accepts BOTH HR+/HER2- AND TNBC patients.

**Solution:** Modified the TNBC exclusion to skip trials that contain "HR+" or " or " in the title, indicating they accept multiple breast cancer subtypes.

```python
# TRIPLE-NEGATIVE trials exclude ER+, PR+, or HER2+
# BUT: Skip if trial also accepts HR+ patients (indicated by "HR+" or "or" in title)
if ("triple-negative" in trial.title.lower() or "TNBC" in trial.title) and \
   not ("HR+" in trial.title or " or " in trial.title):
    if biomarkers.ER == "present" or biomarkers.PR == "present" or biomarkers.HER2 == "positive":
        return "Triple-negative trial requires ER-/PR-/HER2- (patient has positive receptors)"
```

## All Applied Fixes

1. ✅ Disabled hard prior therapy exclusion
2. ✅ Added mutual exclusivity for lung biomarkers (EGFR/ALK/ROS1/KRAS)
3. ✅ Enhanced breast cancer HR+/HER2- matching logic
4. ✅ Added treatment history to confirmation items
5. ✅ Fixed TNBC exclusion logic for multi-subtype trials

## Next Steps After Restart

Once the backend is restarted and showing 6 trials:
1. Test the frontend at http://localhost:8082
2. Enter Patient A profile and verify 6 trials appear
3. Confirm bc_trial_005 "Datopotamab Deruxtecan" is in the results